Alexza resubmits ADASUVE NDA to U.S. FDA Alexza Pharmaceuticals, Inc. announced today that it offers resubmitted its ADASUVE New Drug Software to the U.S. Food and Drug Administration in response to a Total Response Letter received in-may 2012. ADASUVE NDA Regulatory Upgrade In May 2012, Alexza received a CRL from the FDA. The Might 2012 CRL also included comments on Alexza’s draft product labeling. Related StoriesNew evaluation finds illogical thoughts as most predictive of schizophrenia riskNovel study tool identifies hyperlink between negative symptoms of schizophrenia and adverse medical outcomesVraylar capsules right now approved by FDA to take care of schizophrenia, bipolar disorder in adultsThere had been no brand-new clinical or safety problems identified and there have been no other deficiencies outlined in the CRL.The difference in the 10-year local-recurrence rates was calculated with a two-sided 95 percent self-confidence interval by means of the Greenwood formula. The noninferiority hypothesis was tested with the use of a z-verify offset by the noninferiority margin. We used the log-rank test to compare general survival in both groups, and we utilized Cox proportional-hazards models to judge the regularity of treatment results by screening for interactions between the treatment group and subgroups of curiosity. For the subgroup analysis, tumor size was dichotomized as smaller sized than 2 cm or 2 cm or bigger.